Benzinga | Feb 10, 2021 11:17AM EST

Canaccord Genuity Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $22

Canaccord Genuity initiates coverage on Ocuphire Pharma (NASDAQ:OCUP) with a Buy rating and announces Price Target of $22.